Cempra (CEMP) Shares are Down -4.01%

Cempra (CEMP) has risen sharply, recording gains of 9.45% in the past 4 weeks. However, the stock has corrected -4.01% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 10.04% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.06% and the 50-Day Moving Average is 7.99%.The 200 Day SMA reached 22.52%

Cempra

Cempra (NASDAQ:CEMP): After opening at $24.68, the stock dipped to an intraday low of $23.77 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $25 and the buying power remained strong till the end. The stock closed at $24.2 for the day, a gain of 1.34% for the day session. The total traded volume was 1,656,807. The stocks close on the previous trading day was $24.2.

Cempra (CEMP) : 11 investment research analysts covering Cempra (CEMP) have an average price target of $37.82 for the near short term. The highest target price given by the Brokerage Firm to the stock is $51 and the lowest target is $25 for the short term. Analysts expect the variance to be within $7.48 of the average price.

Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.